Global market valuation was derived through production volume mapping and revenue analysis across fermentation-derived and chemically synthesized sources. The methodology included:
The identification of over 40 main manufacturers and biotechnology firms in North America, Europe, Asia-Pacific, and Latin America that specialize in the production of menaquinone
Product mapping across MK-7 (menaquinone-7), MK-4 (menaquinone-4), and combination formulations, segmented by natural (natto/soy fermentation) and synthetic (chemical synthesis) sourcing origins
Analysis of reported and modeled annual revenues specific to Vitamin K2 portfolios, including bulk ingredient sales and finished dosage form valuations
Coverage of manufacturers representing 70-75% of global market share in 2024, encompassing specialized fermentation companies and diversified nutraceutical ingredient suppliers
Extrapolation using bottom-up (production volume × ASP by country/region across supplement, food fortification, and pharmaceutical applications) and top-down (manufacturer revenue validation and patent portfolio analysis) approaches to derive segment-specific valuations for capsules/tablets, powder, and oil formulations